Lumira Ventures partners with exceptional entrepreneurs to build life science companies that transform the lives of patients worldwide.

Lumira News

Aurinia Demonstrates Voclosporin’s Superiority over Standard-of-Care in Lupus Nephritis

December 4, 2019
VICTORIA, British Columbia--(BUSINESS WIRE)-- Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH / TSX:AUP) (“Aurinia” or the “Company”), a late-stage clinical biopharmaceutical company focused... Learn More

Zymeworks & BeiGene Advance ZW25 into Potentially Registration-Enabling Global Studies

November 22, 2019
SINGAPORE -- Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical company developing multifunctional therapeutics, today announced updated Phase 1 data for single-agent ZW25 in... Learn More

Opsens Reports FY2019 Revenues of $32.8M, up 36%

November 14, 2019
QUEBEC CITY, Quebec – Opsens Inc. (“Opsens” or the “Company”) (TSX:OPS) (OTCQX:OPSSF) today reported its results for 2019. Highlights For the Quarter and The Year Record... Learn More

Notch Therapeutics Announces R&D Collaboration with Allogene worth up to $283M per Target

November 5, 2019
SOUTH SAN FRANCISCO, Calif. and TORONTO — Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™)... Learn More

MORE NEWS

Team Lumira

Our investment team of 9 professionals has over 225 years of collective experience founding, managing and investing in healthcare and life sciences companies. We value collaboration, creativity and challenging conventional wisdom.

MEET THE TEAM
Image

Philanthropy

Lumira donates a portion of partner time and profits to support the research, translational medicine and healthcare access missions of over a dozen leading healthcare foundations.

LEARN MORE

  • “Lumira’s philanthropic vision of leveraging research, resources and knowledge to improve the lives of patients will strengthen St. Michael’s ability to accelerate the pace.”

    Dr. Arthur Slutsky | Vice-President
    Vice-President of Research at St. Michael’s Hospital

  • “Lumira’s model provides a new pathway for philanthropy to partner with investors in advancing healthcare innovation.”

    Barbara Grantham | President & Ceo
    VGH & UBC Hospital Foundation

  • “This distinctive approach to supporting innovation is very creative, very much needed and very much appreciated by Princess Margaret and University Health Network.”

    Paul Alofs | President & Ceo
    Princess Margaret Cancer Foundation

Contact Us

Our team is strategically situated across North America to identify innovative companies within and outside the traditional start-up hubs, and help them access capital, talent and strategic partners.

Image

Toronto

141 Adelaide Street
Suite 770
Toronto, ON
Canada, M5H 3L5
416.213.4223

Image

Montreal

Espace CDPQ
3, Place Ville Marie
Bureau 12350, Niveau L
Montreal, QC
Canada, H3B 0E7
514.844.6927

Image

Vancouver

1021 West Hastings Street,
9th floor
Vancouver, BC
Canada, V6E 0C3
604.558.5156

Image

Boston

303 Wyman Street
Suite 300
Waltham, MA,
USA, 02451-1208
781.530.3868